Guardant Health, Inc. (GH)
GHNASDAQ-GSMedical Specialities
$142.45
-1.58 (-1.10%) today
Regular session, Nov 17, 10:58 AM ET
- Market cap
- $19.27bn
- P/E
- –
- EPS, last 4 quarters
- $-3.67
- Dividend yield
- –
- Day range
- $141.25 to $148.96
- 52-week range
- $74.55 to $191.05
- Average volume
- –
- Previous close
- $144.03
Analysts
20 coveringBuy19 buy, 1 hold, 0 sell
Targets a year out average $204.00, +43.2% from here
Earnings
next estimate $-0.7300Next report
Dec 2025
-23.5%
Mar 2026
-19.7%
Jun 2026
-20.3%
Sep 2026
-36.8%
estimate reported, and the surprise
Financials
| Quarter | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| Revenue | $281.27m | $301.67m | $334.98m | $360.98m |
| Gross profit | $181.77m | $196.75m | $219.03m | $236.15m |
| Operating income | -$120.81m | -$121.35m | -$129.12m | -$132.76m |
| Net income | -$128.49m | -$112.08m | -$120.14m | -$124.36m |
Last four quarters: revenue $1.28bn, margin -37.9%, free cash flow -$232.15m
News
8 latest- Guardant Health, Inc. Completes $550 Million Offering of 0% Convertible Senior Notes due 2032Fintel · 10 hours ago
- Guardant Health (GH) Q3 2026 Earnings Call TranscriptThe Motley Fool · Nov 6, 2026
- What Guardant Health (GH) Said on Its Q3 Earnings CallMarketBeat · Nov 5, 2026
- Guardant Health (GH) Reports Q3 Loss, Tops Revenue EstimatesZacks · Nov 5, 2026
- Guardant Health (GH) Q3 Earnings: How Key Metrics Compare to Wall Street EstimatesZacks · Nov 5, 2026
- Cytokinetics (CYTK) Reports Q3 Loss, Beats Revenue EstimatesZacks · Nov 4, 2026
- Countdown to Guardant Health (GH) Q3 Earnings: Wall Street Forecasts for Key MetricsZacks · Nov 4, 2026
- Guardant Health, Inc. Grants 465,413 Target Performance-Based Restricted Stock Units to Each Co-CEOFintel · Nov 3, 2026
The company
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer.
- Sector
- Health Care
- Industry
- Medical Specialities
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- guardanthealth.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.